Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Dec 05, 2020 1:19pm
556 Views
Post# 32044129

ATM further comment

ATM further commentThis is an edited version of a post I made on Yahoo Finance:

In my view, this is not an unexpected move. It creates the opportunity to sell into strength if or when they care to do so. They do not have to sell any shares at all. I do not think the intent is to create liquidity for a partnership. If an investor wants to buy a big hunk of the company, the board can just vote to change the share structure (e.g., a new share class). In sum, I think this is a positive move to increase liquidity if they want to do so.

I am not worried about the so-called dilution. I have posted too many times on this board why worrying about dilution in a company like this ill-placed if not foolish. This company is improving and refining its intellectual property every quarter, and has nothing to sell but its intellectual property. As the expected value of the IP goes up, the expected value that can be realized through SP increases and ultimately through future revenues increases. Simply surviving, reviewing its data from past trials, and carrying on with current trials has improved the expected value of the company enormously. So please, no more bleating about dilution.
<< Previous
Bullboard Posts
Next >>